Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017651 | 0.69 | GAA (0.37) | KMT2AALDH1A1GAAKDM4ETGFBR1 | |
| SCHEMBL10038836 | 0.67 | ALDH1A1 (0.39) | KMT2AALDH1A1GAAKDM4EMAPK1 | |
| SCHEMBL3593067 | 0.65 | ALDH1A1 (0.40) | KMT2AALDH1A1GAAKDM4EMAPK1 | |
| SCHEMBL7242330 | 0.64 | KDM4E (0.36) | ALDH1A1KDM4E | |
| SCHEMBL2745021 | 0.64 | LTA4H (0.38) | — | |
| SCHEMBL7241923 | 0.64 | ACSS2 (0.34) | KMT2AALDH1A1 | |
| SCHEMBL7238158 | 0.64 | ACSS2 (0.30) | — | |
| SCHEMBL9342327 | 0.64 | L3MBTL1 (0.41) | KMT2AALDH1A1GAAKDM4E | |
| SCHEMBL1179209 | 0.62 | CA2 (0.42) | ALDH1A1 | |
| SCHEMBL3598537 | 0.62 | KDM4E (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2094689-B1 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| EP-2094689-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074752-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | RB1, INMT, IDH3A | KMT2A 1726/4885SLC2A2 4298/4885MTNR1B 153/4885 |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | IDH3A, IDH2, INMT | KMT2A 1846/4885SLC2A2 2956/4885MTNR1B 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.